Chengdu Kanghong Pharmaceutical amends articles, revises board structure

Chengdu Kanghong Pharmaceutical Group held its first extraordinary general meeting of shareholders for 2025 on December 19, 2025. Key resolutions passed include the amendment of the company's registered capital and articles of association, which received 99.9899% approval from voting shares, and the revision of several internal policies. Notably, the "Rules of Procedure for the Shareholders' Meeting" and "Rules of Procedure for the Board of Directors" were approved with 95.4764% and 95.4728% of voting shares, respectively. Other policies adopted included the "Independent Director System," "Related Party Transaction Management Measures," "External Investment Management System," "External Guarantee Management System," and "Raised Funds Management System."

The meeting also addressed personnel changes. Mr. Yin Jinqun resigned from his directorship and position on the strategic committee due to governance structure adjustments. He will continue to serve in other roles within the company and its subsidiaries. Following his resignation, Mr. Yin Jinqun, who holds 351,350 shares (0.04% of total shares), was elected as a worker representative director for the eighth board of directors and a member of the strategic committee. These changes ensure the company's compliance with legal requirements regarding board composition.